Aliment Pharmacol Ther

1. LEDING C, Meddis A, Holler JG, Burisch J, et al
   Pathogen-Specific Bloodstream Infections Associated With Tumour Necrosis Factor-alpha Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case-Control Study 2010-2024.
   Aliment Pharmacol Ther. 2026 Sep 24. doi: 10.1111/apt.70999.
   

   >> Share

   
   
2. YAGUE CABALLERO C, Garcia-Lopez S, Casas-Deza D
   Editorial: Treatment Sequencing in Inflammatory Bowel Disease-Does the Line Matter More Than the Mechanism? Authors' Reply.
   Aliment Pharmacol Ther. 2026 Sep 22. doi: 10.1111/apt.71006.
   

   >> Share

   
   
3. TRUNIGER S, Brand S
   Editorial: Anti-Integrin alphavbeta6 Autoantibodies for Distinguishing Ulcerative Colitis From Crohn's Disease: Authors' Reply.
   Aliment Pharmacol Ther. 2026 Sep 22. doi: 10.1111/apt.71002.
   

   >> Share

   
   
4. MOHTA S, Kutum R, Dhoundiyal A, Pendyala R, et al
   Development and Prospective Validation of a Machine Learning-Based Mobile Application (CROHN'S AID) for Differentiating Crohn's Disease From Intestinal Tuberculosis in Tuberculosis-Endemic Regions.
   Aliment Pharmacol Ther. 2026 Sep 21. doi: 10.1111/apt.70984.
   

   >> Share

   
   

   
   Clin Exp Immunol

5. HONJO H, Watanabe T, Otsuka Y, Masuta Y, et al
   Nucleotide-binding oligomerization domain 2-independent colonization by Turicimonas muris induced by high-fat diet protects against dextran sodium sulfate-induced colitis.
   Clin Exp Immunol. 2026;220:uxag057.
   

   >> Share

   
   

   
   Clin Gastroenterol Hepatol

6. R G, R F, N G, S C, et al
   Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage therapy.
   Clin Gastroenterol Hepatol. 2026 Sep 22:S1542-3565(26)00719.
   

   >> Share

   
   
7. DALAL RS, Silvestri ME, Kwaning KM, Carlin AD, et al
   Guselkumab Versus Risankizumab for Ulcerative Colitis: Real-World Comparison of Post-Induction Outcomes.
   Clin Gastroenterol Hepatol. 2026 Sep 23:S1542-3565(26)00721.
   

   >> Share

   
   
8. GOYAL MK, Lee A, Shah D, Brehmer S, et al
   Managing IBS-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Meta-Analysis of Randomized Trials.
   Clin Gastroenterol Hepatol. 2026 Sep 25:S1542-3565(26)00725.
   

   >> Share

   
   

   
   Drugs

9. FAGGIANI I, Tuttle C, Danese S, Peyrin-Biroulet L, et al
   Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies.
   Drugs. 2026;86:1577-1597.
   

   >> Share

   
   

   
   Eur J Gastroenterol Hepatol

10. DIVAKARLA S, Hinckfuss C, Cruz C, Luo H, et al
    The role of bioelectrical impedance analysis in assessing sarcopenia in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2026 Aug 12. doi: 10.1097/MEG.0000000000003265.
    

    >> Share

    
    
11. NAPOLITANO D, Bozzetti M, Scaldaferri F, Gasbarrini A, et al
    Generational differences in illness perception among adults with inflammatory bowel disease: a multicenter cross-sectional study.
    Eur J Gastroenterol Hepatol. 2026 Aug 27. doi: 10.1097/MEG.0000000000003266.
    

    >> Share

    
    
12. SABHAN H, Bello F, Muhsen S, Johansson F, et al
    Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE).
    Eur J Gastroenterol Hepatol. 2026 Sep 1. doi: 10.1097/MEG.0000000000003274.
    

    >> Share

    
    

    
    Inflamm Bowel Dis

13. HE D, Sha S, Liu X, Yin P, et al
    Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study.
    Inflamm Bowel Dis. 2026 Sep 23:izag185. doi: 10.1093.
    

    >> Share

    
    
14. LE BERRE C, Rezazadeh Ardabili A, Czepielewski R, Cices A, et al
    Revisiting the role of lymphatics in Crohn's disease.
    Inflamm Bowel Dis. 2026 Sep 23:izag187. doi: 10.1093.
    

    >> Share

    
    
15. EDELMAN-KLAPPER H, Avni-Biron I, Ollech JE, Hegger S, et al
    Long-term outcomes of patients with negative small bowel video capsule endoscopy for Crohn's disease: A cohort study.
    Inflamm Bowel Dis. 2026 Sep 24:izag188. doi: 10.1093.
    

    >> Share

    
    
16. GISBERT JP, Chaparro M
    Biologics, small molecules, and extraintestinal malignancies in inflammatory bowel disease: practical questions and evidence-based answers.
    Inflamm Bowel Dis. 2026 Sep 25:izag192. doi: 10.1093.
    

    >> Share

    
    

    
    J Crohns Colitis

17. JACOBS I, Ceulemans M, Lenfant M, Cremer J, et al
    Distinct intestinal eosinophil subsets in ulcerative colitis and their modulation by advanced inflammatory bowel disease therapies.
    J Crohns Colitis. 2026;20:jjag141.
    

    >> Share

    
    
18. SRINIVASAN AR, Sagami S, Nguyen A, Smith RL, et al
    Evaluating sonographic response and remission in inflammatory bowel disease: aligning intestinal ultrasound assessment with STRIDE-II timelines.
    J Crohns Colitis. 2026;20:jjag132.
    

    >> Share

    
    
19. LEES RD, Patel P, Young G, Beck L, et al
    Orofacial granulomatosis associated with Crohn's disease: clinical phenotype and response to biologics and Janus kinase inhibitor therapy in a large multi-center cohort.
    J Crohns Colitis. 2026;20:jjag139.
    

    >> Share

    
    
20. SPENCER EA, Cohen S, Dubinsky MC, Suskind DL, et al
    Upadacitinib treatment in pediatric Crohn's disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN.
    J Crohns Colitis. 2026;20:jjag125.
    

    >> Share

    
    
21. KATANO T, Okabayashi S, Yamazaki H, Matsubayashi M, et al
    Effectiveness and safety of tacrolimus versus infliximab as rescue therapy for intravenous corticosteroid-refractory acute severe ulcerative colitis: a multicenter cohort study.
    J Crohns Colitis. 2026;20:jjag143.
    

    >> Share

    
    
22. GADEOCK S, King M, Polk DB, Highton AJ, et al
    Targeting epithelial IFN-I signaling restores barrier integrity in anti-TNF refractory Crohn's disease.
    J Crohns Colitis. 2026;20:jjag140.
    

    >> Share

    
    

    
    PLoS One

23. SU Y, Luo X, Xu H
    Correction: Apoptosis-related genes bridge inflammatory bowel disease and osteoporosis: A bioinformatic analysis.
    PLoS One. 2026;21:e0359291.
    

    >> Share

    
    
24. KAZI MAI, Mufarrih SM, Sirohi A, Hasan F, et al
    Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study.
    PLoS One. 2026;21:e0358659.
    

    >> Share

    
    

    
    Scand J Gastroenterol

25. SOUAID C, Buisson A, Jeay M, Skinazi F, et al
    Exploring obstacles to physical activity in inflammatory bowel disease: insights from a survey.
    Scand J Gastroenterol. 2026 Sep 24:1-3. doi: 10.1080/00365521.2026.2736875.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share